2018 Atrial Fibrillation Drug Development- Pipeline Analysis Report

April 2018 | | ID: 202C599607DEN
VPAResearch

Abstracts

Atrial Fibrillation or AFib is estimated to affect around 30 million worldwide and is currently regarded as an important research area. With increasing aged population (65+) across several countries, Atrial fibrillation is observed to be one of the leading causes of strokes with strong increase in hospitalization rates. Over 30 companies and universities are focusing on developing treatment options for Atrial Fibrillation.

To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Atrial Fibrillation pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Atrial Fibrillation pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Atrial Fibrillation pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 ATRIAL FIBRILLATION PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Atrial Fibrillation Pipeline Snapshot
2.3 Atrial Fibrillation Pipeline by Phase
2.4 Atrial Fibrillation Pipeline by Company
2.5 Atrial Fibrillation Pipeline by Mechanism of Action

3 ATRIAL FIBRILLATION- COMPANY WISE PIPELINE ANALYSIS

Acesion Pharma Aps
Allosteros Therapeutics Inc
AnaBios Corporation
ARCA biopharma, Inc.
AstraZeneca
Bayer
Boston Pharmaceuticals
Bristol-Myers Squibb
Dong-A Socio Holdings Co Ltd
Edge Therapeutics, Inc
Gilead Sciences, Inc.
HUYA Bioscience International
InCarda Therapeutics, Inc.
Johnson & Johnson Pharmaceutical Research & Development
Medtronic, Inc
Merck & Co
NeuroSearch
N-Gene Research Laboratories, Inc.
Nissan Chemical Industries, Ltd.
Novartis Pharmaceuticals
Nyken
OMEICOS Therapeutics GmbH
Ono Pharmaceutical
Pierre Fabre
Sanofi
ST Pharm
Syntex Pharmaceuticals International
The Geneva Biotech Center SA
Verseon
Xention

4 ATRIAL FIBRILLATION R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ATRIAL FIBRILLATION PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Atrial Fibrillation Pipeline by Phase, H1- 2018
Figure 2: Atrial Fibrillation Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Atrial Fibrillation Pipeline by Mechanism Of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Atrial Fibrillation Pipeline by Phase, H1- 2018
Table 2: Atrial Fibrillation Pipeline by Companies, H1- 2018
Table 3: Atrial Fibrillation Pipeline by Mechanism Of Action, H1- 2018
Table 4: Acesion Pharma Aps Atrial Fibrillation Pipeline, May 2018
Table 5: Allosteros Therapeutics Inc Atrial Fibrillation Pipeline, May 2018
Table 6: AnaBios Corporation Atrial Fibrillation Pipeline, May 2018
Table 7: ARCA biopharma, Inc. Atrial Fibrillation Pipeline, May 2018
Table 8: AstraZeneca Atrial Fibrillation Pipeline, May 2018
Table 9: Bayer Atrial Fibrillation Pipeline, May 2018
Table 10: Boston Pharmaceuticals Atrial Fibrillation Pipeline, May 2018
Table 11: Bristol-Myers Squibb Atrial Fibrillation Pipeline, May 2018
Table 12: Dong-A Socio Holdings Co Ltd Atrial Fibrillation Pipeline, May 2018
Table 13: Edge Therapeutics, Inc Atrial Fibrillation Pipeline, May 2018
Table 14: Gilead Sciences, Inc. Atrial Fibrillation Pipeline, May 2018
Table 15: HUYA Bioscience International Atrial Fibrillation Pipeline, May 2018
Table 16: InCarda Therapeutics, Inc. Atrial Fibrillation Pipeline, May 2018
Table 17: Johnson & Johnson Pharmaceutical Atrial Fibrillation Pipeline, May 2018
Table 18: Medtronic, Inc Atrial Fibrillation Pipeline, May 2018
Table 19: Merck & Co Atrial Fibrillation Pipeline, May 2018
Table 20: NeuroSearch Atrial Fibrillation Pipeline, May 2018
Table 21: N-Gene Research Laboratories, Inc. Atrial Fibrillation Pipeline, May 2018
Table 22: Nissan Chemical Industries, Ltd. Atrial Fibrillation Pipeline, May 2018
Table 23: Novartis Pharmaceuticals Atrial Fibrillation Pipeline, May 2018
Table 24: Nyken Atrial Fibrillation Pipeline, May 2018
Table 25: OMEICOS Therapeutics GmbH Atrial Fibrillation Pipeline, May 2018
Table 26: Ono Pharmaceutical Atrial Fibrillation Pipeline, May 2018
Table 27: Pierre Fabre Atrial Fibrillation Pipeline, May 2018
Table 28: Sanofi Atrial Fibrillation Pipeline, May 2018
Table 29: Sanofi; University Hospital Regensburg Atrial Fibrillation Pipeline, May 2018
Table 30: ST Pharm Atrial Fibrillation Pipeline, May 2018
Table 31: Syntex Pharmaceuticals International Atrial Fibrillation Pipeline, May 2018
Table 32: The Geneva Biotech Center SA Atrial Fibrillation Pipeline, May 2018
Table 33: Verseon Atrial Fibrillation Pipeline, May 2018
Table 34: Xention Atrial Fibrillation Pipeline, May 2018